Lymphoma down arrow


Hodgkin Lymphoma



Therapy For Intermediate Risk Patients


The COG research protocol AHOD0031 was designed for intermediate risk Hodgkin lymphoma and included the following patients:

Intermediate Risk Hodgkin Lymphoma:

Stage IA or IIA with bulky disease


Stage IB or IIB disease


Stage IIIA disease


The aim of this study was to:

  • Evaluate response-based therapy
  • Evaluate dose-intensive therapy
  • To improve outcome and reduce the incidence of long term complication
  • Link with COG biological studies


Outline of therapy:

Initial 2 cycles of ABVE-PC - (dose intensification - each cycle was 21 days). G-CSF used for support.


A = Doxorubicin (Adriamycin)

B = Bleomycin

V = Vincristine

E = Etoposide

P = Prednisone

C = Cyclophosphamide

Rapid Early Responders:

1. Received another 2 cycles of ABVE-PC

2. Then (after 4 cycles of ABVE-PC) had been given - if there was a complete response, RERs were randomized to receive involved field radiation therapy (IFRT) or no further treatment.

Partial Responders:

Patients who achieved:

  • a Very Good Partial Response (VGPR)
  • Partial Response  (PR)
  • Stable Disease (SD)

Slow Early Responder randomized either to standard arm (2 further cycles) or augmented arm (4 further cycles including 2 non-cross reacting cycles) of chemotherapy.

All were given involved field RT

Progressive disease:

These patients were taken off the study and treated as per a high risk protocol


AHOD0031 was closed in 2009 as it had met accrual requirements.

Preliminary results to be presented at ASH Meeting 2011:

"Early response to chemotherapy is important in the optimization of subsequent treatment intensity in patients with HL."

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children’s Oncology Group







Back to top